320 related articles for article (PubMed ID: 32030795)
1. NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer.
Dong C; Yin F; Zhu D; Cai X; Chen C; Liu X
J Cell Biochem; 2020 Nov; 121(11):4470-4483. PubMed ID: 32030795
[TBL] [Abstract][Full Text] [Related]
2. Low expression of NCALD is associated with chemotherapy resistance and poor prognosis in epithelial ovarian cancer.
Feng LY; Li L
J Ovarian Res; 2020 Mar; 13(1):35. PubMed ID: 32228639
[TBL] [Abstract][Full Text] [Related]
3. Low Expression of SLC7A11 Confers Drug Resistance and Worse Survival in Ovarian Cancer
Ke Y; Chen X; Su Y; Chen C; Lei S; Xia L; Wei D; Zhang H; Dong C; Liu X; Yin F
Front Oncol; 2021; 11():744940. PubMed ID: 34790572
[TBL] [Abstract][Full Text] [Related]
4. NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer.
Konrad SM; Schwamborn K; Krüger A; Honert K; Schmitt M; Hellmann D; Schmalfeldt B; Meindl A; Kiechle M; Quante AS; Brambs C; Grill S; Ramser J
Biomark Med; 2022 Oct; 16(14):1029-1041. PubMed ID: 36444691
[No Abstract] [Full Text] [Related]
5. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
[TBL] [Abstract][Full Text] [Related]
6. Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling.
Tan WX; Sun G; Shangguan MY; Gui Z; Bao Y; Li YF; Jia ZH
Sci Rep; 2020 Sep; 10(1):14768. PubMed ID: 32901049
[TBL] [Abstract][Full Text] [Related]
7. Microarray-based identification of genes associated with prognosis and drug resistance in ovarian cancer.
Yin F; Yi S; Wei L; Zhao B; Li J; Cai X; Dong C; Liu X
J Cell Biochem; 2019 Apr; 120(4):6057-6070. PubMed ID: 30335894
[TBL] [Abstract][Full Text] [Related]
8. Long non-coding RNA MIDEAS-AS1 inhibits growth and metastasis of triple-negative breast cancer via transcriptionally activating NCALD.
Luo D; Liang Y; Wang Y; Ye F; Jin Y; Li Y; Han D; Wang Z; Chen B; Zhao W; Wang L; Chen X; Jiang L; Yang Q
Breast Cancer Res; 2023 Sep; 25(1):109. PubMed ID: 37770991
[TBL] [Abstract][Full Text] [Related]
9. [Bioinformatics analysis of drug-resistant ceRNA in epithelial ovarian cancer].
Pan ZM; Tan FC; Chen CX; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2021 Feb; 56(2):121-130. PubMed ID: 33631884
[No Abstract] [Full Text] [Related]
10. HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer.
Jiang J; Wang S; Wang Z; Cai J; Han L; Xie L; Han Q; Wang W; Zhang Y; He X; Yang C
Cancer Chemother Pharmacol; 2020 Aug; 86(2):295-305. PubMed ID: 32743678
[TBL] [Abstract][Full Text] [Related]
11. Identification of MEG8/miR-378d/SOBP axis as a novel regulatory network and associated with immune infiltrates in ovarian carcinoma by integrated bioinformatics analysis.
Lei J; He ZY; Wang J; Hu M; Zhou P; Lian CL; Hua L; Wu SG; Zhou J
Cancer Med; 2021 Apr; 10(8):2924-2939. PubMed ID: 33742531
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Analysis of the Expression and Prognosis for Laminin Genes in Ovarian Cancer.
Diao B; Yang P
Pathol Oncol Res; 2021; 27():1609855. PubMed ID: 34512203
[TBL] [Abstract][Full Text] [Related]
13. Roles of a TMPO-AS1/microRNA-200c/TMEFF2 ceRNA network in the malignant behaviors and 5-FU resistance of ovarian cancer cells.
Li H; Zhou Y; Cheng H; Tian J; Yang S
Exp Mol Pathol; 2020 Aug; 115():104481. PubMed ID: 32497621
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of transient receptor potential cation channel, subfamily C, member 1 contributes to drug resistance and high histological grade in ovarian cancer.
Liu X; Zou J; Su J; Lu Y; Zhang J; Li L; Yin F
Int J Oncol; 2016 Jan; 48(1):243-52. PubMed ID: 26647723
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target.
Li W; Huang L; Qi N; Zhang Q; Qin Z
BMC Genomics; 2024 Feb; 25(1):183. PubMed ID: 38365611
[TBL] [Abstract][Full Text] [Related]
16. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.
Xu L; Zhang B; Li W
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576437
[TBL] [Abstract][Full Text] [Related]
17. LINC-PINT suppresses tumour cell proliferation, migration and invasion through targeting miR-374a-5p in ovarian cancer.
Hao T; Huang S; Han F
Cell Biochem Funct; 2020 Dec; 38(8):1089-1099. PubMed ID: 32638404
[TBL] [Abstract][Full Text] [Related]
18. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.
Kanlikilicer P; Bayraktar R; Denizli M; Rashed MH; Ivan C; Aslan B; Mitra R; Karagoz K; Bayraktar E; Zhang X; Rodriguez-Aguayo C; El-Arabey AA; Kahraman N; Baydogan S; Ozkayar O; Gatza ML; Ozpolat B; Calin GA; Sood AK; Lopez-Berestein G
EBioMedicine; 2018 Dec; 38():100-112. PubMed ID: 30487062
[TBL] [Abstract][Full Text] [Related]
19. Role of the KRT7 Biomarker in Immune Infiltration and Paclitaxel Resistance in Ovarian.
Wang S; Li H; Li M; Liu X; Yu S; Huang H; Wang X
Altern Ther Health Med; 2023 Jul; 29(5):132-140. PubMed ID: 37023314
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of bromodomain PHD finger transcription factor in ovarian cancer and its critical role for cancer cell proliferation and survival.
Miao J; Zhang M; Huang X; Xu L; Tang R; Wang H; Han S
Biochem Cell Biol; 2021 Jun; 99(3):304-312. PubMed ID: 32985220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]